Document Detail

Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients.
MedLine Citation:
PMID:  10958764     Owner:  NLM     Status:  MEDLINE    
The heterozygous 32 base pair deletion of the chemokine receptor 5 (Delta32CCR5) has been associated with a more benign course of HIV-1-infection. To study the influence of Delta32CCR5 on the response to antiviral therapy we analyzed the presence of Delta32CCR5 by PCR in PBMC from 107 randomly selected HIV-1-infected patients treated with HAART for at least three months. 24 of 107 patients were heterozygous for Delta32CCR5 (22.4%). Before initiation of HAART Delta32CCR5 heterozygous patients (d/w) did not differ from homozygous CCR5 wild-type patients (w/w) regarding viral load and CD4 counts. After a median treatment time on HAART of 17.5 months (d/w, range 6-31 months, p = n.s.) or 19 months (w/w, range 3-33 months) all 24 patients (100%) with the Delta32CCR5 mutation, but only 58/83 patients (69.9%) with wild-type CCR5 showed a suppression of HIV-1-viremia below 500 copies/ml (p = 0.0020). Furthermore, 20/24 (83.3%) of the Delta32CCR5 heterozygous patients achieved CD4 counts above 200/microliter, but only 57/83 (68.7%) of the patients homozygous for CCR5 wild-type (p = 0.011). Our data indicate that the presence of heterozygous Delta32CCR5 is associated with a better response to HAART suggesting that therapeutic strategies targeting CCR5 could be of value for a sustained suppression of HIV-1 by HAART.
S Kasten; A Goldwich; M Schmitt; A Rascu; M Grunke; C Dechant; J R Kalden; T Harrer
Related Documents :
22909794 - Determinants of preserved diastolic function at the lateral annulus in patients with is...
15990954 - Glutathione synthetase deficiency.
10639204 - Sleep-disordered breathing in duchenne muscular dystrophy: a preliminary study of the r...
18786134 - Anderson's disease (chylomicron retention disease): a new mutation in the sara2 gene as...
1864104 - Value of transesophageal echocardiography as an adjunct to transthoracic echocardiograp...
10525694 - The arrow versus horizontal suture in arthroscopic meniscus repair. a prospective rando...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of medical research     Volume:  5     ISSN:  0949-2321     ISO Abbreviation:  Eur. J. Med. Res.     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-09-26     Completed Date:  2000-09-26     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  9517857     Medline TA:  Eur J Med Res     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  323-8     Citation Subset:  IM; X    
Department of Medicine III, University of Erlangen-Nuremberg, Krankenhausstrasse 12, D-91054 Erlangen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acquired Immunodeficiency Syndrome / drug therapy*,  genetics*
Anti-HIV Agents / therapeutic use*
Cohort Studies
Dideoxynucleosides / therapeutic use*
Drug Resistance, Microbial / genetics
Lamivudine / therapeutic use
Receptors, CCR5 / genetics*
Zidovudine / therapeutic use
Reg. No./Substance:
0/Anti-HIV Agents; 0/Dideoxynucleosides; 0/Receptors, CCR5; 134678-17-4/Lamivudine; 30516-87-1/Zidovudine; WR2TIP26VS/abacavir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-r...
Next Document:  Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HI...